BIOR Stock Overview
A clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Biora Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.67 |
| 52 Week High | US$19.90 |
| 52 Week Low | US$1.43 |
| Beta | 1.28 |
| 11 Month Change | -57.18% |
| 3 Month Change | -75.65% |
| 1 Year Change | -87.63% |
| 33 Year Change | -99.82% |
| 5 Year Change | n/a |
| Change since IPO | -99.95% |
Recent News & Updates
Shareholder Returns
| BIOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.2% | 2.5% | 2.2% |
| 1Y | -87.6% | 16.1% | 31.6% |
Return vs Industry: BIOR underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: BIOR underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| BIOR volatility | |
|---|---|
| BIOR Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BIOR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 58 | Adi Mohanty | www.bioratherapeutics.com |
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Biora Therapeutics, Inc. Fundamentals Summary
| BIOR fundamental statistics | |
|---|---|
| Market cap | US$6.14m |
| Earnings (TTM) | -US$35.57m |
| Revenue (TTM) | US$892.00k |
6.9x
P/S Ratio-0.2x
P/E RatioIs BIOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOR income statement (TTM) | |
|---|---|
| Revenue | US$892.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$892.00k |
| Other Expenses | US$36.47m |
| Earnings | -US$35.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.67 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,988.12% |
| Debt/Equity Ratio | -36.9% |
How did BIOR perform over the long term?
See historical performance and comparison